Bacteriocins from interbacterial warfare as antibiotic alternative

BACtheWINNER aims to develop novel antimicrobials from bacteriocins through advanced bioengineering and molecular genetics to combat antimicrobial resistance and improve human and animal health.

Subsidie
€ 2.500.000
2023

Projectdetails

Introduction

Antimicrobial resistance (AMR) is an ongoing global crisis exacerbated by the lack of discovery of novel antimicrobials and the absence of investment/innovation in pipelines by the pharmaceutical industry. New alternatives that are target-specific and do not cause collateral damage to the microbiome would revolutionize human and animal health.

Bacteriocins Overview

Bacteriocins are small antibacterial peptides produced by bacteria that are gene-encoded and can be narrow or broad spectrum. They have potential for the development of new antimicrobial molecules through discovery and protein engineering, resulting in potent, targeted antimicrobials.

Applications of Bacteriocins

They have many possible applications including:

  • Treatment of gut and topical infections
  • Microbiome editing

Challenges in Bacteriocin Exploitation

However, basic research issues stand in the way of their exploitation, including:

  1. Low production levels often in unsuitable hosts
  2. Resistance development in bacterial targets
  3. Inadequate potency/inhibition spectrum

Project Aim

The main aim of BACtheWINNER is to develop bacteriocins as novel antimicrobials by solving these challenges through combining and innovating state-of-the-art technologies in peptide bioengineering and molecular genetics. This will lay the foundation for the generation of this new family of therapeutics that target WHO and CDC priority pathogens and undesirable microbiota.

Development Pipeline

To achieve this, a four-phase bacteriocin discovery and development pipeline will be implemented, which includes:

  1. Taking new and existing bacteriocins and improving them through bioengineering
  2. Developing optimal combinations
  3. (Over-)producing them in desirable hosts
  4. Validating their use in preclinical models of human infection and disease

This will pave the way for their development as precision microbiome tools and antimicrobials against AMR pathogens.

Expertise and Collaboration

We bring together unique expertise necessary to deliver this project by combining bacteriocin and microbiome research with genetic manipulation of food and gut bacteria.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.500.000
Totale projectbegroting€ 2.500.000

Tijdlijn

Startdatum1-4-2023
Einddatum31-3-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORKpenvoerder
  • TEAGASC - AGRICULTURE AND FOOD DEVELOPMENT AUTHORITY

Land(en)

Ireland

Vergelijkbare projecten binnen European Research Council

ERC STG

MANUNKIND: Determinants and Dynamics of Collaborative Exploitation

This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.

€ 1.497.749
ERC STG

Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure

The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.

€ 1.498.280
ERC STG

Uncovering the mechanisms of action of an antiviral bacterium

This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.

€ 1.500.000
ERC STG

The Ethics of Loneliness and Sociability

This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.

€ 1.025.860

Vergelijkbare projecten uit andere regelingen

ERC COG

In situ genetic perturbation of gut bacteria with engineered phage vectors and CRISPR

This project aims to develop synthetic biology tools for precise genetic manipulation of gut bacteria using phage vectors and CRISPR-Cas systems to enhance microbiome-targeted therapies.

€ 1.999.780
ERC COG

Exploiting plasmid–bacteria interactions to fight the evolution of antimicrobial resistance

PLAS-FIGHTER aims to develop innovative strategies against plasmid-mediated antimicrobial resistance by exploring plasmid-induced physiological effects in bacteria using advanced screening and ecological models.

€ 1.999.573
ERC STG

Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered Prophages

PHAGE-PRO aims to revolutionize phage therapy by utilizing engineered prophages and probiotics for rapid pathogen targeting and sustained efficacy, enhancing infection management in livestock and human medicine.

€ 1.500.000
EIC Accelerator

A novel combination treatment effective against all multidrug-resistant pathogens deemed as a critical priority by the WHO

Developing a combination of meropenem and ANT3310 to combat drug-resistant Gram-negative infections, aiming for market approval by 2029 and projected sales over €10bn in 13 years.

€ 2.500.000